174 related articles for article (PubMed ID: 34361754)
1.
Hogendorf A; Hogendorf AS; Kurczab R; Satała G; Szewczyk B; Cieślik P; Latacz G; Handzlik J; Lenda T; Kaczorowska K; Staroń J; Bugno R; Duszyńska B; Bojarski AJ
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361754
[TBL] [Abstract][Full Text] [Related]
2. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Kołaczkowski M; Marcinkowska M; Bucki A; Śniecikowska J; Pawłowski M; Kazek G; Siwek A; Jastrzębska-Więsek M; Partyka A; Wasik A; Wesołowska A; Mierzejewski P; Bienkowski P
Eur J Med Chem; 2015 Mar; 92():221-35. PubMed ID: 25557493
[TBL] [Abstract][Full Text] [Related]
3. Virtual screening-driven discovery of dual 5-HT
Staroń J; Kurczab R; Warszycki D; Satała G; Krawczyk M; Bugno R; Lenda T; Popik P; Hogendorf AS; Hogendorf A; Dubiel K; Matłoka M; Moszczyński-Pętkowski R; Pieczykolan J; Wieczorek M; Zajdel P; Bojarski AJ
Eur J Med Chem; 2020 Jan; 185():111857. PubMed ID: 31734022
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT
Zajdel P; Grychowska K; Mogilski S; Kurczab R; Satała G; Bugno R; Kos T; Gołębiowska J; Malikowska-Racia N; Nikiforuk A; Chaumont-Dubel S; Bantreil X; Pawłowski M; Martinez J; Subra G; Lamaty F; Marin P; Bojarski AJ; Popik P
J Med Chem; 2021 Sep; 64(18):13279-13298. PubMed ID: 34467765
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT
Saavedra OM; Karila D; Brossard D; Rojas A; Dupuis D; Gohier A; Mannoury la Cour C; Millan MJ; Ortuno JC; Hanessian S
Bioorg Med Chem; 2017 Jan; 25(1):38-52. PubMed ID: 28029458
[TBL] [Abstract][Full Text] [Related]
6. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models.
Ivachtchenko AV; Ivanenkov YA; Veselov MS; Okun IM
Curr Alzheimer Res; 2017; 14(3):268-294. PubMed ID: 27829340
[TBL] [Abstract][Full Text] [Related]
7. A dual-acting 5-HT
Canale V; Grychowska K; Kurczab R; Ryng M; Keeri AR; Satała G; Olejarz-Maciej A; Koczurkiewicz P; Drop M; Blicharz K; Piska K; Pękala E; Janiszewska P; Krawczyk M; Walczak M; Chaumont-Dubel S; Bojarski AJ; Marin P; Popik P; Zajdel P
Eur J Med Chem; 2020 Dec; 208():112765. PubMed ID: 32949963
[TBL] [Abstract][Full Text] [Related]
8. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
[TBL] [Abstract][Full Text] [Related]
9. Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
Bucki A; Marcinkowska M; Śniecikowska J; Więckowski K; Pawłowski M; Głuch-Lutwin M; Gryboś A; Siwek A; Pytka K; Jastrzębska-Więsek M; Partyka A; Wesołowska A; Mierzejewski P; Kołaczkowski M
J Med Chem; 2017 Sep; 60(17):7483-7501. PubMed ID: 28763213
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain.
Kusumi I; Takahashi Y; Suzuki K; Kameda K; Koyama T
J Neural Transm (Vienna); 2000; 107(3):295-302. PubMed ID: 10821438
[TBL] [Abstract][Full Text] [Related]
12. New hexahydrocarbazoles and spiro indoles, and their affinity for D2 dopamine and 5-HT2A serotonin receptors.
Fernández F; García-Mera X; Rodríguez G; Urrutia A
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1006-9. PubMed ID: 10434402
[TBL] [Abstract][Full Text] [Related]
13. The impact of the halogen bonding on D
Partyka A; Kurczab R; Canale V; Satała G; Marciniec K; Pasierb A; Jastrzębska-Więsek M; Pawłowski M; Wesołowska A; Bojarski AJ; Zajdel P
Bioorg Med Chem; 2017 Jul; 25(14):3638-3648. PubMed ID: 28529043
[TBL] [Abstract][Full Text] [Related]
14. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
Norman MH; Rigdon GC; Navas F; Cooper BR
J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
[TBL] [Abstract][Full Text] [Related]
15. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
Andersen K; Liljefors T; Hyttel J; Perregaard J
J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
[TBL] [Abstract][Full Text] [Related]
16. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents.
Homan EJ; Copinga S; Elfström L; van der Veen T; Hallema JP; Mohell N; Unelius L; Johansson R; Wikström HV; Grol CJ
Bioorg Med Chem; 1998 Nov; 6(11):2111-26. PubMed ID: 9881101
[TBL] [Abstract][Full Text] [Related]
17. Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
Yan Y; Zhou P; Rotella DP; Feenstra R; Kruse CG; Reinders JH; van der Neut M; Lai M; Zhang J; Kowal DM; Carrick T; Marquis KL; Pausch MH; Robichaud AJ
Bioorg Med Chem Lett; 2010 May; 20(9):2983-6. PubMed ID: 20347298
[TBL] [Abstract][Full Text] [Related]
18. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel N
Nirogi RV; Bandyala TR; Gangadasari PR; Khagga M
J Enzyme Inhib Med Chem; 2016; 31(sup1):1-15. PubMed ID: 27806648
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.
Smid P; Coolen HK; Keizer HG; van Hes R; de Moes JP; den Hartog AP; Stork B; Plekkenpol RH; Niemann LC; Stroomer CN; Tulp MT; van Stuivenberg HH; McCreary AC; Hesselink MB; Herremans AH; Kruse CG
J Med Chem; 2005 Nov; 48(22):6855-69. PubMed ID: 16250644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
